Retatrutide Waitlist: How to Be First
Everyone wants retatrutide. Supply will be limited at launch. Here is how to position yourself for the earliest possible access -- and what to do productively while you wait.
After retatrutide's Phase 2 results (Jastreboff et al., NEJM 2023) showed 24% weight loss, patient interest exploded. The question shifted from "does this work?" to "how do I get it?" But retatrutide is not yet FDA-approved, supply through any channel is limited, and demand far exceeds availability. Smart positioning now can mean earlier access later.
Access Reality
No official waitlist exists for retatrutide. Beware of scams charging for "waitlist" access or "guaranteed early supply." Retatrutide is investigational and not FDA-approved.
Step 1: Start Treatment Now
The most productive thing you can do while waiting for retatrutide is start losing weight with currently available medications. Compounded semaglutide ($99/mo) offers 15-17% weight loss. Compounded tirzepatide ($125/mo) offers 20-22% weight loss. Both are effective, well-characterized treatments that work. Starting now means you build a relationship with a prescribing provider, establish baseline health data, begin your weight loss journey immediately, and position yourself for an easy transition to retatrutide when available.
Step 2: Establish a Provider Relationship
Telehealth providers that specialize in weight loss medications will be among the first to offer retatrutide access when it becomes available -- whether through compounding pharmacies or FDA-approved channels. Having an existing patient relationship means faster access compared to starting from scratch.
Step 3: Consider Clinical Trial Enrollment
Phase 3 trials (TRIUMPH program) provide the most assured access to pharmaceutical-grade retatrutide with comprehensive medical monitoring. Search ClinicalTrials.gov for active enrollment opportunities. Discuss eligibility with your physician.
Step 4: Stay Informed
Follow reputable medical sources for retatrutide news. FDA decisions, trial results, and availability updates will come through medical journals, FDA announcements, and legitimate medical news sources -- not social media speculation.
What Not to Do
- Do not pay for "waitlist" access -- legitimate waitlists are free
- Do not buy research peptides labeled as retatrutide
- Do not postpone weight loss waiting for a "better" medication
- Do not believe guaranteed availability dates from unofficial sources
To start your weight loss journey today, visit our treatments page.
Medical Disclaimer
This article is for educational purposes only. Retatrutide is not FDA-approved. No official waitlist exists. Consult a healthcare provider for treatment decisions.
Do Not Wait -- Start Today
Effective weight loss treatments available now. Semaglutide from $99/mo.
Get Started TodayMore on Retatrutide
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).